A knee arthroscopy gets cancelled in the pre-op bay because someone mentions, almost in passing, that they take a weekly injection for weight. Six months earlier the same disclosure would have produced a shrug. Somewhere between those two dates the anesthesia profession worked out that standard fasting rules were written for stomachs that empty on schedule.
The first formal response, an American Society of Anesthesiologists advisory issued in June 2023, told prescribers to hold daily GLP-1 formulations on the day of a procedure and weekly formulations for a full week. That advice spread quickly, and a great many people still receive it verbatim. It is no longer what the consensus documents say.
Multisociety guidance published in 2024 by anesthesiology, gastroenterology and bariatric surgery organizations replaced the blanket hold with individualized risk assessment, preparation with a clear liquid diet, and bedside gastric ultrasound where doubt remains. A 2025 consensus statement from the Society for Perioperative Assessment and Quality Improvement in the British Journal of Anaesthesia landed in the same place. What follows explains the mechanism behind the concern, what the guidance actually asks for, and what a person on a low dose protocol should say when the pre-op questionnaire asks about medications.
Key Takeaways
- The 2024 multisociety perioperative guidance does not recommend routinely stopping GLP-1 receptor agonists before procedures. It replaces the earlier blanket hold with individualized risk assessment, preoperative diet modification, and gastric point-of-care ultrasound when concern about retained contents exists on the day.
- A clear liquid diet for at least 24 hours before a procedure is the specific preparation the guidance names when delayed gastric emptying is a concern. This is the same preparation already used before colonoscopy and bariatric surgery.
- Standard preoperative fasting rules allow solids up to six to eight hours and clear liquids up to two hours before anesthesia. Those intervals were derived from normal gastric emptying and can fail to clear a stomach on a GLP-1 receptor agonist.
- Endoscopy series report residual gastric contents in appropriately fasted GLP-1 users at several times the rate seen in non-users, though reported figures vary substantially by study design and by how residual content is defined.
- Gastric emptying delay is most pronounced in the weeks after starting or increasing a dose and attenuates with continued exposure, which is why published risk frameworks weight recent escalation more heavily than long-term stable dosing.
- Stopping a GLP-1 receptor agonist before surgery carries its own cost in people using it for type 2 diabetes, since perioperative hyperglycemia is independently associated with worse surgical outcomes.
Where a Solid Meal Is at Hour Six
Approximate share of a standardized solid test meal still in the stomach, percent remaining
- No GLP-1
- On GLP-1 therapy
Illustrative of the separation reported in scintigraphy and paracetamol absorption studies rather than a reproduction of a single published curve. The point is the gap at hour six, which is where the standard solid fasting rule expects an empty stomach. Individual variation around both curves is wide enough that group averages predict very little about any one person.
Why does the anesthesia team care about gastric emptying?
Four steps from a slowed stomach to an airway problem
General anesthesia suppresses the reflexes that keep stomach contents out of the airway, so the entire fasting apparatus exists to guarantee an empty stomach at the moment those reflexes disappear. GLP-1 receptor agonists slow gastric emptying deliberately, because slowing it is part of how the drugs blunt appetite. The therapeutic mechanism and the perioperative concern are the same physiological effect viewed from two directions.
The fasting rules encode an assumption about time
Standard guidance allows clear liquids up to two hours and a light solid meal up to six hours before anesthesia, with heavier meals pushed to eight. Those intervals came from studies of gastric emptying in people not taking anything that alters it. The rule is not a measurement of any individual stomach, it is a population estimate that has worked well enough for decades.
Slowed emptying breaks the assumption rather than the rule
A GLP-1 receptor agonist does not make the stomach dangerous, it makes the clock wrong. Someone who has genuinely eaten nothing for eight hours may still hold solid residue that the eight hour rule was designed to exclude. Nothing about the fasting instruction was violated, which is precisely why the situation catches teams by surprise.
The consequence is aspiration, which is rare and serious
Pulmonary aspiration during elective anesthesia is uncommon, reported in the range of a few events per 10,000 procedures in large audits. When it happens it can cause chemical pneumonitis, respiratory failure and prolonged intensive care. Low frequency combined with high severity is the profile that justifies systematic precautions rather than reassurance.
Anesthesia has established answers for a full stomach
Rapid sequence induction secures the airway quickly to narrow the window in which aspiration can occur, and it is used routinely for emergency surgery in people who ate recently. Delaying an elective case is the other standard option. Both require knowing in advance, which converts the problem from a hazard into a planning question.
Residual Gastric Contents in Fasted Patients
Approximate share found to have retained contents on point-of-care ultrasound, percent
Approximate magnitudes assembled from endoscopy and preoperative ultrasound series rather than a pooled reanalysis, and published figures vary widely depending on how retained content is defined. The highlighted bar is the diet modification arm, which is the intervention the guidance actually recommends. Note that a 24 hour liquid diet appears to do more work here than holding the dose does.
What changed between the 2023 advice and the current guidance?
From a fixed hold to an individualized assessment
The 2023 ASA advisory was a rapid response to case reports, and it did what rapid responses do: it picked a simple rule that was easy to follow. Hold daily formulations on the day, hold weekly formulations for a week. Simplicity was the point, because there was very little data and a lot of anxious anesthesiologists.
Two problems emerged over the following year. The first is that a one week hold does not reliably empty the stomach, since semaglutide has a half life of about a week and a single missed dose leaves substantial drug exposure in place. The second is that cessation carries real costs, particularly for people taking these medications for type 2 diabetes, where withdrawal collides with the hyperglycemia that surgical stress produces anyway.
The 2024 multisociety guidance replaced the fixed rule with three components: assess the individual, modify the preoperative diet with clear liquids for at least 24 hours where emptying is a concern, and use gastric ultrasound on the day when doubt persists. The 2025 SPAQI consensus statement in the British Journal of Anaesthesia reached compatible conclusions. Both documents describe the final decision as shared between the patient, the procedural team, the anesthesia team and whoever prescribes the medication.
What the Liquid Diet Window Appears to Buy
Approximate share with residual gastric contents by duration of preoperative clear liquid diet, percent
Illustrative gradient consistent with the rationale given for the 24 hour recommendation rather than a measured dose-response, since trials comparing liquid diet durations in this population are still recruiting. Clear liquids empty from the stomach far faster than solids even when emptying is slowed, which is the mechanism the recommendation relies on. Nobody should improvise a fasting plan from a chart like this.
Who is actually considered higher risk?
The features the guidance asks teams to look for
Recent dose escalation is the feature that carries the most weight, because gastric emptying delay peaks in the weeks after a dose is started or raised and then attenuates with continued exposure. Someone three weeks into a titration step sits in a different place than someone who has held the same dose for eight months. That tachyphylaxis is well described and is the main reason a fixed hold interval never fitted the physiology.
Active gastrointestinal symptoms are the second signal, and they are the one a patient can report without any testing. Nausea, vomiting, early satiety, abdominal distension or a sense that food is sitting in the stomach all suggest the delay is currently clinically apparent rather than subclinical. A person with those symptoms on the morning of a procedure is describing the exact thing the guidance is trying to detect.
Underlying conditions that already slow the stomach compound everything above. Long-standing type 2 diabetes with autonomic neuropathy produces gastroparesis independently of any medication, and layering a GLP-1 receptor agonist on top of that is a different proposition than prescribing it to someone with normal baseline motility. Prior gastric surgery, Parkinson disease and several classes of medication including opioids and anticholinergics belong in the same category.
Features That Raise Perioperative Concern
Illustrative relative weight assigned to individual risk features, index
Constructed index reflecting the ordering of features described in published risk stratification frameworks, not a validated score and not usable to classify anyone. No scoring system for this situation has been prospectively validated against aspiration outcomes. The ordering is the only informative part, and even the lowest bar is not a zero.
Aspiration Events per 10,000 Anesthetics
Approximate reported rates of pulmonary aspiration across settings
Approximate magnitudes drawn from large anesthetic audit literature and early GLP-1 case series, not a matched comparison, and the GLP-1 figure rests on far thinner data than the others. Absolute rates are low across every bar, which is why the discussion is about margin rather than about likelihood. Event counts this small produce very wide confidence intervals.
Does a lower dose change what should happen before surgery?
A plausible argument with no perioperative outcome data behind it
The mechanistic case is straightforward. Gastric emptying delay is dose-related, it is most pronounced during titration, and it attenuates over months of stable exposure. A protocol that stays at a small maintenance dose for a long time never spends much time in the part of that relationship where emptying is most disturbed. Published risk frameworks already treat recent escalation and high maintenance dose as the features to watch, which is the same ordering read from the other end.
No study has tested this. There is no trial comparing residual gastric contents or aspiration events across deliberately reduced GLP-1 doses, and the perioperative literature that does exist is dominated by people on approved dosing for obesity or diabetes. Everything in the paragraph above is inference from a dose-response relationship applied to a question nobody has measured, and that kind of inference has a mixed record.
None of it changes the disclosure obligation. A person on 0.25 mg weekly is taking the same drug class the pre-op questionnaire is asking about, and describing it as a microdose does not remove it from the list. The anesthesia team is entitled to weigh the dose, the duration, the last injection date and the symptom picture, and they can only do that with the information in front of them. Withholding it to avoid a cancelled procedure is the one genuinely poor decision available here.
Modeled Retained Contents by Days Since Injection
Modeled share with residual gastric contents by dose tier, percent
- Microdose
- Mid dose
- Full dose
Modeled by applying a one week elimination half life to a dose-scaled starting point, not measured, and no study has tracked residual gastric contents across dose tiers or across days since injection. The dashed line marks day seven, the interval the 2023 advisory recommended, and the modeled curves barely fall by then. That shallow decline is a large part of why the fixed hold was abandoned.
What should someone on a protocol do before a scheduled procedure?
Six things to raise, none of them self-directed
Everything below is general information for a conversation rather than a plan to follow. The fasting and medication instructions for any specific procedure come from the team performing it, and those instructions override anything written here.
Pre-operative assessment happens days or weeks ahead precisely so that plans can be adjusted without cancelling anything. A GLP-1 receptor agonist disclosed at booking becomes a diet instruction, while the same medication disclosed in the pre-op bay becomes a scheduling problem. Name the drug, the dose, how long it has been at that dose, and the date of the last injection.
Some centres still apply the 2023 advisory and will ask for a one week hold, while others follow the 2024 multisociety approach with diet modification instead. Both are defensible positions taken by people responsible for the outcome. Asking which one applies produces a clear instruction rather than a guess assembled from conflicting things read online.
Nausea, vomiting, early satiety, bloating or a sense of food sitting undigested are the symptoms that shift someone into a higher concern category. These are also the symptoms people minimise, because they have become normal on therapy and feel unrelated to a knee operation. They are the most useful information available without a scan.
Gastric emptying delay peaks in the weeks after starting or raising a dose and settles with continued exposure, which makes a recent titration step more relevant than the absolute number of milligrams. Someone two weeks into a new dose warrants different handling than someone stable for a year. This detail is rarely asked for directly, so it usually has to be volunteered.
Point-of-care gastric ultrasound turns an estimate into an observation on the morning of the procedure and is named in the 2024 guidance for exactly that purpose. Not every centre has an anesthetist trained in it or a machine free. Knowing the answer ahead of time shapes how conservative the rest of the plan needs to be.
Stopping a GLP-1 receptor agonist before surgery has real costs, particularly for glycemic control in type 2 diabetes at the moment surgical stress raises blood glucose. The decision to hold, continue or adjust belongs to the prescribing and anesthesia teams jointly. Unilaterally skipping a dose because of something read online removes them from a decision they are accountable for.
What is genuinely unresolved here?
Three gaps the current guidance openly acknowledges
The outcome that matters has barely been measured. Almost all of the perioperative literature reports residual gastric contents on ultrasound or endoscopy, which is a surrogate, and very little reports aspiration itself. Aspiration during elective anesthesia is rare enough that detecting a difference between groups would require a study far larger than anything conducted so far. Retained contents are easy to count and clinically ambiguous, and the guidance is built on them because nothing better exists yet.
The 24 hour clear liquid recommendation is reasoned rather than trialled. It borrows a preparation already validated for colonoscopy and bariatric surgery and applies it to a new problem on the sound basis that liquids clear faster than solids even when emptying is slowed. Trials comparing liquid diet durations specifically in GLP-1 users are registered and recruiting, and until they report, the 24 hour figure is a considered judgement rather than a measured optimum.
Dose tiers below approved dosing sit outside the evidence entirely. Every perioperative study in this area recruited people on standard obesity or diabetes dosing, so nothing published describes what happens at deliberately reduced doses, and the modeled curve in this article is inference rather than data. That gap does not make a low dose protocol riskier, and it does not make it safer either. It means the honest answer to a question about microdosing and anesthesia is that nobody has measured it, and the disclosure and planning steps apply regardless.
Frequently Asked Questions
Selected References
- Kindel TL, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clinical Gastroenterology and Hepatology, Surgical Endoscopy and Surgery for Obesity and Related Diseases, 2024.
- Society for Perioperative Assessment and Quality Improvement. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists, multidisciplinary consensus statement. British Journal of Anaesthesia, 2025.
- American Society of Anesthesiologists. Patients taking GLP-1 receptor agonists prior to elective procedures, presidential advisory. June 2023.
- American Society of Anesthesiologists. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration.
- Perlas A, Chan VW, Lupu CM, et al. Ultrasound assessment of gastric content and volume. Anesthesiology.
- Sherwin M, et al. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound. Journal of Clinical Anesthesia, 2023.
- Jalleh RJ, Jones KL, Rayner CK, et al. Normal and disordered gastric emptying in diabetes and the effects of GLP-1 receptor agonists. Diabetologia.
- Novo Nordisk and Eli Lilly. Prescribing information for semaglutide and tirzepatide, sections on gastric emptying and gastrointestinal adverse reactions.
This article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications are prescription drugs, and any dosing strategy, including low dose or microdosing approaches, should be decided and monitored by a qualified healthcare provider. Nothing here is intended to diagnose, prevent, treat, or cure obesity, diabetes, gastroparesis, or any other condition, and no low dose or microdosing approach described here has been shown to reduce aspiration risk or any other perioperative risk. Fasting instructions and medication holds before any procedure must come from the surgical and anesthesia teams performing it, and their instructions override everything written here. Do not stop, delay, or adjust a prescribed medication before a procedure because of anything in this article, and do not withhold information about any medication from a pre-operative assessment. Several charts here are illustrative or modeled rather than measured outcomes, and the figures given are approximations of published literature rather than exact reproductions. Individual results vary.
Smaller Doses. Sharper Protocols.
Metabolic health you can measure, built around a dose designed to work with your body rather than against it.
Find Your Protocol